CEFACLOR VERSUS CLARITROMYCIN IN ACUTE BRONCHITIS

ELI LILLY INTERAMERICA INC.,0 个研究点目标入组 0 人开始时间: 2000年10月2日最近更新: 2023年9月4日

适应症

试验速览

暂无简介。

•1. Diagnosis of acute bronchitis and having a chest x-ray at the time of assignment to a treatment to exclude pneumonia.
•2. Over 18 years of age or, with a minimum weight of 37 kg. Women of childbearing age (between 18 and 45 years old) with negative pregnancy test in blood and with commitment to use a reliable method of birth control during the study period.
•3. Patients, who in the opinion of the investigator are able to comply with the instructions.
•4. Sign an informed consent document approved by the Ethics Committee.

•5. Have received a systemic antimicrobial therapy within 7 days prior to the assignment to a therapy.
•6. Anticipated requirement of systemic antibiotics other than the study antibiotic after the pre-therapy evaluation and before the
•post-therapy evaluation.
•7. Pregnant women and women who are breastfeeding.
•8. Inability of the individual to swallow tablets
•9. History of renal and / or hepatic insufficiency.
•10. Concomitant infection (tuberculosis or suspected pneumonia) that in the opinion of the investigator may alter the evaluation of the response to a therapy.
•11. Have received a research agent within the last 30 days.
•12. Known immediate hypersensitivity to cephalosporin or penicillin.
•13. Patients with cystic fibrosis.
•14. Patients, who suffer or have suffered in the past six months of symptomatic infection of the Epstein-Barr virus.
•15. Patients, who may require a hospitalization during their participation in the study.
•16. Patient´s inability to return to the follow-up visit.
•17. Patients, who have previously completed or who have withdrawn from this study.
•18. Researchers and their immediate families. The immediate family is defined as the researcher´s wife, parents, children or siblings.

发起方